NEW YORK (AP) — Teva has offered to buy Mylan in a cash-and-stock deal valued at about $40.1 billion. The potential combination would result in a powerhouse of a generic drug developer competing against rivals such as Sun Pharma. Teva Pharmaceutical Industries Ltd.Read more on NewsOK.com